Previous close | 181.79 |
Open | 184.91 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 181.79 - 184.91 |
52-week range | 144.81 - 207.67 |
Volume | |
Avg. volume | 420 |
Market cap | 89.858B |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | 35.86 |
EPS (TTM) | 5.09 |
Earnings date | 13 Aug 2024 |
Forward dividend & yield | 2.46 (1.35%) |
Ex-dividend date | 11 Mar 2024 |
1y target est | N/A |
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent influenza vaccine (QIVc) prevented more test-confirmed influenza cases among individuals 4–64 years of age compared with the egg-based quadrivalent influenza vaccine (QIVe) over three consecutive U.S. influenza seasons (2017–2020).1 These data add to the growing wealth of evidence supporting the benefits o
Applications for camp that offers free world-class AI education to help prepare students for latest tech evolution are now openPHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching students about the latest developments in the world of AI and Generative AI, the c